Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat in Advanced Solid Tumors and B-cell Lymphomas
NCT01897571Phase 2Completed
- Sponsor
- Epizyme, Inc.
- Start
- Jun 2013
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of tazemetostat in solid tumor (advanced stage), B cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Epizyme, Inc.. Started Jun 2013; status: completed.
02
Drugs
tazemetostat
03
Conditions
solid tumor (advanced stage)B cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT01897571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01897571.